Reimbursed Care Access in Greenland

Currently classified as a strictly controlled substance under international psychotropic substance scheduling and national drug control frameworks, with no authorised medical use outside approved clinical research in Greenland. The active principles psilocybin and psilocin are listed on international psychotropic schedules and countries in the Nordic region treat psilocybin-containing material as narcotics for criminal law purposes; Greenlanders seeking clinical access would need to participate in an authorised clinical trial or access an authorised medicinal product under specific, exceptional regulatory pathways. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Clinical MDMA therapy (e.g., MAPS‑sponsored protocols) would require explicit regulatory approval to operate inside Greenland and is not part of routine publicly funded mental‑health services. # #.

Esketamine (Spravato) is authorised in the European Union for treatment‑resistant major depressive disorder and is distributed under the EMA product authorisation with a supervised‑use program. The EMA product assessment and authorisation are documented by the European Medicines Agency; Spravato is indicated for adults with treatment‑resistant major depressive disorder and must be administered under clinical supervision in licensed healthcare settings. #.

Greenland’s healthcare system is publicly funded and regionally delivered by the Government of Greenland (Naalakkersuisut) through regional hospitals (e.g., Queen Ingrid’s Hospital in Nuuk), and medicines procurement and hospital formularies are managed within that public system; there is no public Greenland‑specific, easily discoverable reimbursement list publicly posted that shows a dedicated national outpatient/clinic reimbursement status for Spravato. For these reasons: (a) Spravato is legally authorised in the EU/EMA region and would be the regulated medicine if procured for use in Greenland; (b) practical access in Greenland would require hospital/regional procurement, local clinical‑protocol adoption, and budgetary approval by Greenland’s health authorities or procurement channels — i.e., access is possible but not documented as a routine, nationally reimbursed outpatient programme in publicly available Greenland records. # #.

Reimbursement nuance: within the Kingdom of Denmark medicines reimbursement and procurement normally flow through national/regional procedures; Greenland operates autonomous health administration for many matters and funds hospital care centrally — therefore, if a Greenland regional hospital elected to adopt esketamine for in‑clinic administration, coverage would likely be via the public hospital budget rather than through a separate outpatient pharmacy reimbursement scheme. There is no accessible Greenland government publication (public registry) showing Spravato listed as a routinely reimbursed outpatient drug as of the latest publicly available sources. # #.

Ketamine is an established anaesthetic and analgesic used in hospital settings worldwide and is part of standard emergency and anaesthesia formularies; in Greenland’s publicly funded hospitals ketamine is used for anaesthesia and emergency medicine under licensed, clinician‑supervised use (i.e., standard medical/anaesthetic practice rather than outpatient psychiatric reimbursement). Greenland’s health system provides hospital‑based care through its regional hospitals (e.g., Queen Ingrid’s Hospital, Nuuk), where essential anaesthetics including ketamine are available and supplied by the public system. # #.

Psychedelic/psychiatric uses of ketamine (repeated sub‑anaesthetic infusions for depression) are considered off‑label in many jurisdictions and — if provided in Greenland — would require an institutional clinical protocol, psychiatric oversight, and funding via the hospital/regional health budget; there is no public evidence that Greenland has an established, reimbursed ketamine‑infusion programme for treatment‑resistant depression listed in public procurement or reimbursement databases. Clinicians in Greenland wishing to provide off‑label ketamine for psychiatric indications would need to follow Greenlandic/Danish clinical governance, obtain local institutional approval, and secure hospital funding for the service. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (N,N‑dimethyltryptamine) is internationally scheduled and national law in the Nordic countries treats the compound as a controlled psychotropic; any research or medical use would have to proceed under authorised trial approvals. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as a controlled tryptamine in most European and Nordic national schedules; there is no routine medical programme or reimbursement pathway in Greenland for this compound. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of conventional, publicly funded addiction‑treatment formularies in Greenland; any use would be experimental/clinical trial based and require special approvals. # #.

Currently classified as a strictly controlled substance with legal uncertainty for plant preparations: DMT (the primary active) is internationally controlled, while some countries interpret legal status of plant brews differently. In Greenland there is no authorised medical programme for ayahuasca; importation, distribution, or organisation of ceremonies would be exposed to criminal‑law risk unless conducted within an authorised research protocol. # # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (the active in peyote/Trichocereus cacti) is scheduled internationally; possession/use outside authorised research or tightly regulated religious exemptions (where applicable in other countries) is not permitted in Greenland. # #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C‑series phenethylamine psychedelics (e.g., 2C‑B and related analogues) are widely scheduled internationally and are treated as illegal in the Nordic countries; Greenland has no publicly available programme allowing therapeutic use. # #.